Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide plus standard therapy for CTD-associated interstitial lung disease with obesity/overweight or type 2 diabetes
ChiCTR2600135189Phase 4Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tirzepatide in connective tissue disease-associated interstitial lung disease (CTD-ILD) (2 arms), sponsored by Southwest Hospital of Army Medical University. Primary endpoint: Absolute change in forced vital capacity from baseline. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
03
Conditions
connective tissue disease-associated interstitial lung disease (CTD-ILD)
Beyond the preview
Go deeper on ChiCTR2600135189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135189.